Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trontinemab in early symptomatic Alzheimer's disease
jRCT2031250328Phase 3Recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Trontinemab with Placebo (2 arms). Primary endpoint: Change from baseline to Week 72 in CDR-SB. Started Nov 2025; status: recruiting.
02
Drugs
trontinemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2031250328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250328.